Holen Sie sich die Stockscreener-App
5.0252
3.56%
0.2452
Schlusskurs vom Vortag:
$4.78
Offen:
$4.8
24-Stunden-Volumen:
29,695
Relative Volume:
0.12
Marktkapitalisierung:
$3.37M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-23.72M
KGV:
-0.0517
EPS:
-97.2514
Netto-Cashflow:
$-23.28M
1W Leistung:
+4.87%
1M Leistung:
-39.63%
6M Leistung:
-97.45%
1J Leistung:
-99.21%
1-Tages-Spanne:
$4.80
$5.09
1-Wochen-Bereich:
$4.6101
$5.5885
52-Wochen-Spanne:
$4.30
$658.60
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Firmenname
Aptevo Therapeutics Inc
Sektor
Branche
Telefon
206-838-0500
Adresse
2401 4TH AVE., SEATTLE, WA
Vergleichen Sie APVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.95 | 3.17M | 12.99M | -23.72M | -23.28M | -97.25 |
|
ONC
Beone Medicines Ltd Adr
|
256.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.03 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.28 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
497.53 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-11-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-10-05 | Fortgesetzt | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decrease in Short Interest - Defense World
Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | AP - GuruFocus
Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | APVO Stock News - GuruFocus
Aptevo Therapeutics Approves 1-for-20 Reverse Stock Split - TipRanks
Aptevo Therapeutics Announces Reverse Stock Split - TipRanks
Aptevo Therapeutics to Implement 1-for-20 Reverse Stock Split - marketscreener.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as pa - GuruFocus
Aptevo Therapeutics (APVO) Announces 1-for-20 Reverse Stock Split | APVO Stock News - GuruFocus
Aptevo Therapeutics enacts reverse stock split to maintain Nasdaq compliance - Investing.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo's Dramatic 1:20 Reverse Split Cuts Shares from 13.5M to 0.7M in Nasdaq Compliance Push - Stock Titan
StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World
Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptevo reports high remission in AML patients with new drug By Investing.com - Investing.com South Africa
APVO: Promising Trial Results Propel AML Treatment Innovations | - GuruFocus
APVO: Promising Trial Results Propel AML Treatment Innovations | APVO Stock News - GuruFocus
Aptevo reports high remission in AML patients with new drug - Investing.com Australia
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig | APVO Stock News - GuruFocus
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - ACCESS Newswire
Breakthrough: New AML Drug Shows 90% Remission Rate With Zero Cytokine Release Syndrome - Stock Titan
Aptevo Therapeutics (APVO) Expected to Announce Earnings on Wednesday - Defense World
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Therapeutics Provides Program Update for Bispecific APVO7 - GuruFocus
Aptevo Therapeutics Says In Preclinical Studies APVO711 Demonstrates Dual Anti-Cancer Functionality - marketscreener.com
Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy wit - GuruFocus
Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy with APVO711 Update | APVO Stock News - GuruFocus
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation | APVO Stock News - GuruFocus
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation - ACCESS Newswire
Aptevo Therapeutics announces common stock offering - Investing.com Australia
APVO’s latest rating updates from top analysts. - knoxdaily.com
Strategic Moves Drive Stock Gains For OSR, Lianhe Sowell, And Aptevo - Finimize
Aptevo Therapeutics announces common stock offering By Investing.com - Investing.com Canada
Closing Bell Recap: Aptevo Therapeutics Inc (APVO) Ends at 0.61, Reflecting a -9.31 Downturn - DWinneX
Aptevo Therapeutics announces at-the-market offering - Investing.com Australia
APVO stock plunges to 52-week low, touches $0.59 - Investing.com
APVO stock plunges to 52-week low, touches $0.59 By Investing.com - Investing.com UK
Aptevo Therapeutics announces at-the-market offering By Investing.com - Investing.com India
SEC Form 424B4 filed by Aptevo Therapeutics Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering - ACCESS Newswire
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire
Applied Materials Q2 Earnings: Tech Giant's Financial Results Coming May 15 - Stock Titan
A look into Aptevo Therapeutics Inc (APVO)’s deeper side - Sete News
Aptevo Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com
Evogene (EVGN) Sees Dramatic Surge in Investor Interest Amid Strategic Moves | APVO Stock News - GuruFocus
Market Momentum: Aptevo Therapeutics Inc (APVO) Registers a 9.08 Increase, Closing at 0.69 - DWinneX
Finanzdaten der Aptevo Therapeutics Inc-Aktie (APVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):